NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma

Authors :: Kangning Liu
Charlotte Hasenauer
Michael D. Hogarty
Elizabeth Bruckheimer
Eugene W. Gerner
Andrea T. Flynn
Michelle Haber
Murray D. Norris
Katherine K. Matthay
Susan Groshen
Anasheh Shamirian
David S. Ziegler
Araz Marachelian
Source :: Journal of Clinical Oncology. 36:10558-10558
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 10558Background: MYC drives polyamine expansion to support its oncogenic functions. Ornithine decarboxylase (Odc) is a direct MYC target that is rate-limiting for polyamine synthesis, and is itself...

Tools